American Society of Hematology

SHERPA: Blue

People

  1. Seshan
    Seshan
  2. Zelenetz
    Zelenetz
  3. Younes
    Younes
  4. Batlevi
    Batlevi
  5. Palomba
    Palomba
  6. Noy
    Noy
  7. Dogan
    Dogan
  8. Kumar
    Kumar
  9. Matasar
    Matasar
  10. Horwitz
    Horwitz

Groups

  1. Biostatistics Service (34)
  2. Center for Hematologic Malignancies (34)
  3. Center for Pancreatic Cancer Research (34)
  4. Department of Medicine (34)
  5. Epidemiology and Biostatistics (34)
  6. Hematologic Malignancies, Division of (34)
  7. Lymphoma (34)
  8. Executive Committee, Center for Hematologic Malignancies (22)
  9. Sloan Kettering Institute Postdocs (17)
  10. GSK Faculty (16)
Search Within
  1. "Center for Pancreatic Cancer Research"
  2. "Lymphoma"
Formats
  1. Meeting Abstract (27)
  2. Journal Article (6)
  3. Research Letter (1)
Groups
  1. Biostatistics Service (34)
  2. Center for Hematologic Malignancies (34)
  3. Center for Pancreatic Cancer Research (34)
  4. Department of Medicine (34)
  5. Epidemiology and Biostatistics (34)
  6. Hematologic Malignancies, Division of (34)

More Groups

People
  1. Venkatraman Seshan (31)
  2. Andrew Zelenetz (23)
  3. Anas Younes (19)
  4. Ahmet Dogan (17)
  5. Connie Batlevi (17)
  6. Maria Palomba (15)

More People

Years
  1. 2023 (5)
  2. 2022 (3)
  3. 2021 (6)
  4. 2020 (4)
  5. 2019 (3)
  6. 2017 (1)

More Years

Publications
  1. Blood (31)
  2. Blood Advances (3)

Results (34)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes of sequential CD19-directed therapies in relapsed and refractory large B cell lymphoma
    Meeting Abstract

    Qualls, D. A.; Lambert, N.; Caimi, P. F.; Merrill, M. H.; Pullarkat, P.; Godby, R. C.; Bond, D. A.; Wehmeyer, G.; Romancik, J. T.; Amoozgar, B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Genetic alterations of follicular lymphoma can predict response to very low dose radiotherapy
    Meeting Abstract

    Wijetunga, N. A.; Lebow, E.; Chan, A.; Fregonese, B.; Seshan, V.; Hajj, C.; Cederquist, G.; Hubbeling, H.; Ma, J.; Sarkar, R. R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-world outcomes in patients with transformed follicular lymphoma treated with CD19-targeting CAR-T therapy
    Meeting Abstract

    Rivas-Delgado, A.; Luttwak, E.; Drill, E.; Goldstein, I.; Landego, I.; Tomas, A. A.; Parascondola, A.; Saldia, A.; Caron, P.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A multicenter phase 2 trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in patients with treatment-naïve, TP53-mutant mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Soumerai, J.; Abramson, J. S.; Barnes, J. A.; Caron, P.; Chabowska, M.; Devlin, M.; Dogan, A.; Falchi, L.; Garcia, R. N.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study
    Research Letter

    Qualls, D. A.; Lambert, N.; Caimi, P. F.; Merrill, M.; Pullarkat, P.; Godby, R. C.; Bond, D. A.; Wehmeyer, G. T.; Romancik, J.; Amoozgar, B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Tafasitamab and lenalidomide in relapsed/refractory large B cell lymphoma (R/R LBCL): Real world outcomes in a multicenter retrospective study
    Meeting Abstract

    Qualls, D.; Buege, M. J.; Dao, P.; Caimi, P. F.; Rutherford, S. C.; Wehmeyer, G.; Romancik, J. T.; Leslie, L. A.; Merrill, M. H.; Crombie, J. L.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma
    Journal Article

    Qualls, D.; Lam, H. Y.; Whiting, K.; Kumar, A.; Matasar, M.; Owens, C.; Nichols, C.; Espeleta, J. A.; Qiu, A.; Subzwari, S.; more...
    Blood Advances (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save